Results 131 to 140 of about 35,928 (280)

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

A unique case of adrenal insufficiency coexisting with two primary malignancies

, 2023
Hilal Bektaş Uysal, M. Durán, Engın Güney, İrfan Yavaşoğlu, Hulki Meltem Sönmez   +4 more
openalex   +2 more sources

Annual Research Review: What processes are dysregulated among emotionally dysregulated youth? – a systematic review

Journal of Child Psychology and Psychiatry, Volume 66, Issue 4, Page 516-546, April 2025.
Proliferation of the term “emotion dysregulation” in child psychopathology parallels the growing interest in processes that influence negative emotional reactivity. While it commonly refers to a clinical phenotype where intense anger leads to behavioral dyscontrol, the term implies etiology because anything that is dysregulated requires an impaired ...
Joseph C. Blader, Amy S. Garrett, Steven R. Pliszka   +2 more
wiley   +1 more source

MON-164 Determinants of Quality of Life in Primary and Secondary Adrenal Insufficiency from Two Large Tertiary Care Centers in the United States [PDF]

, 2020
Dingfeng Li, Natalia Genere, Majlinda Xhikola, Emma Behnken, Tiffany Abbondanza, Anand Vaidya, Irina Bancos   +6 more
openalex   +1 more source

Epidemiology and Causes of Primary Adrenal Insufficiency in Children: A Population-Based Study [PDF]

, 2023
Joonatan Borchers, ­Eero Pukkala, Outi Mäkitie, Saila Laakso   +3 more
openalex   +1 more source

Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP‐ELM study

Journal of Diabetes Investigation, EarlyView.
Tofogliflozin was compared with metformin in treatment‐naïve people with type 2 diabetes for 4 weeks. Overall insulin secretory capacity did not improve; however, tofogliflozin was associated with an improved disposition index in individuals with poorer baseline glucose tolerance or greater improvement after treatment.
Maiko Miyamoto, Aika Miya, Akinobu Nakamura, Yuka Takahashi, Yuki Yamauchi, Shingo Yanagiya, Takahiro Takase, Mayuko Ono, Kiyohiko Takahashi, Kazufumi Okada, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, on behalf of TOP‐ELM study group, Maiko Miyamoto, Aika Miya, Akinobu Nakamura, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Kazufumi Okada, Rimi Izumihara, Yuki Oe, Takahiro Takase, So Nagai, Akihiro Takahashi, Yuka Takahashi, Yuki Yamauchi, Hiromichi Kijima, Shinji Taneda, Jun Takeuchi, Kei Yokozeki, Saki Kuwabara, Yoshiaki Arimura, Shinichiro Kawata, Tomonori Sekizaki, Yuki Yamauchi, Shingo Yanagiya, Mayuko Ono, Kiyohiko Takahashi   +39 more
wiley   +1 more source

Comment on “Pregnancy Outcomes in Women With Primary Adrenal Insufficiency”: A Call for Broader Multidimensional Assessment [PDF]

Chang Dong, Yan Cui, Mingwei Sima, Donghui Yue   +3 more
openalex   +1 more source

Primary adrenal insufficiency: New genetic causes and their long‐term consequences [PDF]

, 2019
Federica Buonocore, John C. Achermann
openalex   +1 more source

Secondary Adrenal Insufficiency and Primary Hypothyroidism: A Complication of Cancer Immunotherapy

, 2021
Hélard Manrique
openalex   +1 more source

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY)

Journal of Diabetes Investigation, EarlyView.
To investigate the safety of anagliptin/metformin combination tablets in Japanese patients of type 2 diabetes with moderate renal impairment. This study demonstrates that the fixed‐dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction.
Hiroshi Kajio, Ryotaro Bouchi, Mitsuhisa Komatsu, Masanori Yamazaki, Daisuke Takarabe, Masahide Okamoto, Takahisa Tanaka, Toru Kitazawa, Hisayuki Katsuyama, Yasumichi Mori, Mitsuhiko Noda   +10 more
wiley   +1 more source